These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11999464)

  • 41. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.
    Cesinaro AM; Migaldi M; Ferrari G; Castagnetti G; Dotti A; De Gaetani C; Ferrari P; Trentini GP
    Oncol Res; 2000; 12(1):43-9. PubMed ID: 11061345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 and related proteins in epithelial ovarian cancer.
    Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
    Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
    Borre M; Stausbol-Gron B; Overgaard J
    J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
    Zeng L; Rowland RG; Lele SM; Kyprianou N
    Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density.
    Calvocoressi L; Uchio E; Ko J; Radhakrishnan K; Aslan M; Concato J
    J Investig Med; 2018 Dec; 66(8):1142-1146. PubMed ID: 30297390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
    Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
    J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma.
    Matsuura T; Fukuda Y; Fujitaka T; Nishisaka T; Sakatani T; Ito H
    Cancer; 2000 Mar; 88(5):1007-15. PubMed ID: 10699888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
    Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
    Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor formation of prostate cancer cells influenced by stromal cells from the transitional or peripheral zones of the normal prostate.
    Zhao FJ; Han BM; Yu SQ; Xia SJ
    Asian J Androl; 2009 Mar; 11(2):176-82. PubMed ID: 19122679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung.
    Shabnam MS; Srinivasan R; Wali A; Majumdar S; Joshi K; Behera D
    Lung Cancer; 2004 Aug; 45(2):181-8. PubMed ID: 15246189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reliable identification of transition zone prostatic adenocarcinoma in preoperative needle core biopsy.
    Lee S; Walsh S; Woods CG; Bonkhoff H; Cohen RJ
    Hum Pathol; 2013 Oct; 44(10):2331-7. PubMed ID: 23954139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy.
    Al-Ahmadie HA; Tickoo SK; Olgac S; Gopalan A; Scardino PT; Reuter VE; Fine SW
    Am J Surg Pathol; 2008 Feb; 32(2):229-35. PubMed ID: 18223325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
    de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
    Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study.
    Rouvière O; Melodelima C; Hoang Dinh A; Bratan F; Pagnoux G; Sanzalone T; Crouzet S; Colombel M; Mège-Lechevallier F; Souchon R
    Eur Radiol; 2017 May; 27(5):1858-1866. PubMed ID: 27553936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Cell apoptosis and proliferation in the transition and peripheral zones in human prostate].
    Sun HB; Xia SJ
    Zhonghua Nan Ke Xue; 2007 Feb; 13(2):110-3. PubMed ID: 17345763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung.
    Zirbes TK; Lorenzen J; Baldus SE; Moenig SP; Wolters U; Ottlik A; Thiele J; Hölscher AH; Dienes HP
    Histopathology; 1998 Aug; 33(2):123-8. PubMed ID: 9762544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications.
    Mydlo JH; Kral JG; Volpe M; Axotis C; Macchia RJ; Pertschuk LP
    Eur Urol; 1998; 34(5):426-32. PubMed ID: 9803006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia.
    Colombel M; Vacherot F; Diez SG; Fontaine E; Buttyan R; Chopin D
    Br J Urol; 1998 Sep; 82(3):380-5. PubMed ID: 9772874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
    Tamimi Y; van der Poel HG; Karthaus HF; Debruyne FM; Schalken JA
    Br J Cancer; 1996 Aug; 74(4):573-8. PubMed ID: 8761372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.